Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,732.50
Bid: 1,732.50
Ask: 1,733.00
Change: 4.00 (0.23%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chief executives and the itch to quit

Thu, 16th May 2013 07:04

By Andrew Callus

LONDON, May 16 (Reuters) - On approaching his 60th birthdaythis year, long-serving Tullow Oil boss Aidan Heaveytold staff he felt "like two 30 year-olds".

A handful of recent shock departures by 50-something chiefexecutives at European blue chip companies - none of them underany obvious pressure to quit - suggest some of his peers eitherlack that vigour, or want to channel it elsewhere.

Peter Voser is giving up one of the world's most challengingCEO roles at Royal Dutch/Shell next year, before his55th birthday, in pursuit of a "lifestyle change".

Swiss engineering group ABB's 55-year old boss Joe Hogan is also going, for "private reasons". Pierre-OlivierBeckers, 53, is walking out on Belgian retailer Delhaize, and Paul Walsh, 57, is waving goodbye to drinksmultinational Diageo.

All four are about average European CEO age.

While the rising financial rewards of running a modernmultinational have been well publicised, executive recruiterssay the pressures of the job have also been ratcheted up inrecent years, and not just because of the tough economic times.

"The reality is it's gruelling. It's really tough, and therecomes a point where you don't want to do it any more," said IanButcher, who headhunts board-level and senior executives for MWMConsulting.

"The quarterly reporting, the governance, the regulatoryaspects, it just becomes very wearing - the level of scrutiny,the pace at which things are moving, the short-term nature ofhow people look at any given situation. Even over the past fiveyears these things have made CEO a tougher position to hold, andthe travel that people have to undertake in these jobs - it'sjust something they run out of steam on."

Some recent early retirees, while still well short oftraditional retirement age, also got to the top spot early.

"They're still in their early fifties, with energy and adesire to do something, but they want to do something different,something quite significantly different sometimes," saysButcher.

Voser fits that bill. He has no plans to collect well-paidchairmanships and non-executive directorships, as many ex-CEOshave done in the past. Former Tesco chief Terry Leahyhas also resisted that gravy train since he left two years ago.

As for the early starters, executive search industryprofessionals point at people like Andrew Witty, the CEO ofGlaxoSmithKline, who took on the job aged 44 in 2008 andwould have to stay in harness for another decade to reach 60 inthe role.

Blue-chip bosses as young as Witty are still rare, but overa quarter of Europe's current crop have less than two years inthe job, and more than half have less than four, according todata from executive search specialists BoardEx.

MEDIAN CEO AGE IS 55 YEARS

The BoardEx data, collected for Reuters from 238 companiesin the main stock indexes of Germany, Britain, France, Spain,Italy, Belgium, the Netherlands and Denmark, puts the median CEOage at 55, and the median tenure at four years. Only 16 percentof the group have held on for 10 years and more.

The longest serving of them is Martin Gilbert of the Britishfund Aberdeen Asset Management. Though younger, at 57,Gilbert pips the 28.3-year tenure of Tullow's double thirtyyear-old Heavey, with 29.8 years at the helm.

There are 17 top European CEOs who have been in the job forless than six months, and the youngest of the 225 in the groupfor whom ages were available is Vitaly Nesis, 37, who runsPolymetal International, the London-listed Russianprecious metals miner.

While the recent spate of quitters are looking for somethingelse to do, there are still some who appear to want nothing but.

In the BoardEx group there are four over 70, and the oldestby eight years is Albert Frere, CEO of Group Bruxelles Lambert.

Perhaps some linger on for fear that the pension pot isstill a little light. Frere will have put such qualms behind himlong ago. At 87, he is Belgium's richest man.

More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.